What Ritalin (methylphenidate) formulations are available, and is a 27 mg extended‑release dose marketed under the Ritalin brand?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 28, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ritalin Formulations

The Ritalin brand specifically includes immediate-release tablets (5 mg, 10 mg, 20 mg) and Ritalin LA extended-release capsules (10 mg, 20 mg, 30 mg, 40 mg), but a 27 mg dose is NOT marketed under the Ritalin brand name. 1

Available Ritalin Brand Formulations

Immediate-Release Ritalin

The FDA-approved Ritalin immediate-release tablets come in three strengths 1:

  • 5 mg tablets
  • 10 mg tablets
  • 20 mg tablets

These formulations contain methylphenidate hydrochloride with a duration of action of approximately 4 hours 2.

Extended-Release Ritalin LA

Ritalin LA (long-acting) uses microbead technology to provide bimodal delivery with effects lasting approximately 8 hours 3, 2. The available strengths are:

  • 10 mg
  • 20 mg
  • 30 mg
  • 40 mg

The Ritalin LA formulation delivers methylphenidate in a pattern that mimics immediate-release methylphenidate given twice daily, 4 hours apart, with two distinct peak plasma concentrations 3.

The 27 mg Dose Clarification

A 27 mg extended-release methylphenidate formulation exists, but it is NOT part of the Ritalin brand family. The 27 mg dose is available as:

  • OROS-MPH (Concerta) in Japan, Malaysia, and Republic of Korea 4
  • MPH-ER (generic extended-release) in Malaysia 4

The OROS-MPH system uses osmotic pump technology (not microbead technology like Ritalin LA) and provides 12-hour duration of action, which differs mechanically and pharmacokinetically from Ritalin formulations 2.

Clinical Implications

When prescribing, recognize that:

  • Ritalin brand products are limited to the specific doses listed above
  • If a patient requires 27 mg dosing, you must prescribe a different brand (typically Concerta/OROS-MPH or generic extended-release methylphenidate)
  • The pharmacokinetic profiles differ between brands: Ritalin LA provides 8-hour coverage with bimodal peaks, while OROS-MPH provides 12-hour coverage with ascending pharmacokinetics 5, 2

Common prescribing pitfall: Assuming all methylphenidate extended-release products are interchangeable. They are not—the delivery systems, duration of action, and peak concentration patterns vary significantly between Ritalin LA, Concerta (OROS-MPH), Metadate CD, and other formulations 5, 6.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.